Phase II proof-of-concept trial of IkT 001 for the treatment of JC polyomavirus infection in patients with relapsing multiple sclerosis receiving natalizumab.

Trial Profile

Phase II proof-of-concept trial of IkT 001 for the treatment of JC polyomavirus infection in patients with relapsing multiple sclerosis receiving natalizumab.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2011

At a glance

  • Drugs Imatinib (Primary)
  • Indications Polyomavirus infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 24 Aug 2011 New trial record
    • 16 Aug 2011 US FDA grants clearance to begin phase II proof-of-concept trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top